GTx management has a lot of experience in the prostate cancer field. Unfortunately, the company's collective know-how hasn't prevented a series of damaging drug development blow-ups from occurring.But GTx is persistent, so the company is now focused on capesaris, an experimental testosterone deprivation therapy for prostate cancer patients. A phase IIb study comparing daily, oral capesaris to an every-three-month injection of Lupron was started this month, with results possible at the end of the year or early in 2012. GTx is developing capesaris to have equivalent efficacy to Lupron, the current standard of care for hormone-dependent prostate cancer patients, but with a better tolerability and side effect profile. If the capesaris data from the phase IIb study are positive, a pivotal phase III study could start in the middle of 2012.